Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
ID: 350887Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/350887

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-035.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced the availability of Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61), aimed at supporting innovative clinical trials that develop significant interventions for rheumatic, musculoskeletal, or skin diseases. This funding opportunity encourages short-term exploratory studies, including first-in-human or Phase I and II trials, with a maximum budget of $600,000 available over a three-year period. The program emphasizes diversity among applicants, welcoming a wide range of institutions and organizations, while requiring adherence to NIH guidelines for scientific rationale and data management. Interested applicants should note that the application deadlines span from February 2024 to November 2026, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-035.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-035.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has announced the funding opportunity for Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61), under Notice of Funding Opportunity number PAR-24-035. This initiative supports clinical trials that aim to develop clinically significant interventions for rheumatic, musculoskeletal, or skin diseases, accommodating a timeline that suits short-term exploration, such as first-in-human or Phase I and II studies. Key details include a maximum budget of $600,000 over three years and application deadlines ranging from February 2024 to November 2026. Eligible applicants include a wide array of institutions, organizations, and individuals, with an emphasis on diversity among participants. The application process requires adherence to rigorous NIH guidelines, including a focus on scientific rationale and the inclusion of robust monitoring and data management plans. Overall, this program aims to facilitate innovative research that could lead to substantial advancements in treatment and understanding of relevant health conditions, leveraging diverse resources and expertise within the scientific community.
    Similar Opportunities
    Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Clinical Observational (CO) Studies focused on musculoskeletal, rheumatic, and skin diseases, under the grant title PAR-24-036. This grant, which does not allow clinical trials, aims to support observational studies that collect critical data to inform future clinical research, particularly regarding disease symptoms, progression, and participant eligibility, while also exploring telehealth and digital outcomes. The initiative is designed to enhance the rigor of future clinical trials through comprehensive data collection from diverse populations, ultimately improving patient outcomes in affected communities. The grant provides up to $475,000 over four years, with applications opening on February 4, 2024, and funding decisions expected by late 2024. Interested applicants can find more information and guidelines at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3), aimed at supporting interventional clinical trials focused on rheumatic, musculoskeletal, and skin diseases. This initiative encompasses a two-phase approach, where the UG3 phase involves trial preparation and the UH3 phase focuses on trial execution, contingent upon meeting specific milestones. The program emphasizes the importance of developing clinical protocols, obtaining IRB approval, and securing necessary resources, while also promoting health equity by engaging individuals with lived experience in the research process. Interested applicants can apply for funding up to $250,000 for the UG3 phase, with a closing date for submissions set for March 4, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-208.html.
    Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small businesses to support the late-stage translation of biomedical and behavioral research results related to arthritis, musculoskeletal, and skin diseases into marketable products. This Small Business Innovation Research (SBIR) grant (PAR-23-032) aims to foster collaboration between academic/non-profit labs and small business concerns (SBCs) to advance diagnostics, treatments, and prevention tools, while specifically excluding clinical trials. The initiative is crucial for bridging laboratory discoveries with real-world applications, ultimately enhancing public health outcomes through medical innovations. Interested applicants can seek funding up to $350,000, with ongoing application cycles from January 2024 to September 2025, and should direct inquiries to grantsinfo@nih.gov for further information.
    Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Ancillary Studies to Ongoing Clinical Projects" funding opportunity through the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support time-sensitive ancillary studies related to active interventional clinical trials or observational studies, enhancing scientific understanding in alignment with the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Eligible applicants include a diverse range of institutions, with a budget cap of $400,000 over two years, and projects must demonstrate time sensitivity and integration with existing studies. Interested parties can find more information and application guidelines at the NIH website, with a submission deadline of December 5, 2025.
    Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Ancillary Studies to Ongoing Clinical Projects funding opportunity (PAR-23-025), aimed at supporting time-sensitive ancillary studies that enhance scientific knowledge related to the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). These studies must utilize existing cohorts, data, and biological samples to explore novel research questions that extend beyond the scope of the parent projects, with an emphasis on collaboration between junior and senior researchers. Grants may provide up to $300,000 per year for a duration of up to four years, with applications accepted until December 6, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) grant. This funding opportunity aims to support projects that address critical needs for clinical trial readiness in rare diseases, specifically by facilitating the development of biomarkers and clinical outcome measures essential for trial design. The initiative is particularly important for advancing research on diseases affecting fewer than 200,000 individuals in the U.S., enhancing the likelihood of successful clinical trials. Applicants can request up to $275,000 over two years, with a submission deadline of October 17, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-159.html.
    NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering a funding opportunity for investigator-initiated exploratory clinical trials under the UG3/UH3 mechanism. This initiative aims to support Phase 1 and Phase 2 clinical trials that address critical questions related to neurological disorders, focusing on studies involving drugs, biologics, devices, and early interventions. The program emphasizes rigorous research design and encourages diverse and innovative research teams, with grants potentially spanning up to five years, beginning with a planning phase before transitioning to execution. Interested applicants can find more information and application details at the provided link, with a submission deadline of March 10, 2025, and no cost-sharing or matching requirement.
    Limited Competition: Small Grant Program for NIAMS K01, K08, K23, and K25 Recipients (R03) (Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Limited Competition Small Grant Program (R03) aimed at supporting recipients of K01, K08, K23, and K25 awards from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This program allows eligible awardees, specifically those in their second to fourth award year who do not yet hold independent R01 grants, to request up to $100,000 in direct costs over a two-year period to enhance their research capabilities, focusing on pilot studies, methodology development, and secondary data analysis, while explicitly excluding clinical trials. The initiative is designed to foster the development of early-career scientists and strengthen the research landscape by generating additional publications and data necessary for future R01 grant applications. Interested applicants must submit their proposals by February 19, 2025, and can find more information and application guidelines at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R03 Small Grant Program to enhance clinical trial readiness for rare diseases, disorders, and syndromes. This initiative aims to support research that identifies critical needs for advancing therapeutics or diagnostics in rare diseases, which are defined as affecting fewer than 200,000 individuals in the U.S., by developing better biomarkers, clinical outcome measures, and insights into the natural history of these conditions. The program emphasizes the importance of partnerships among researchers, industry, and patient advocacy groups to optimize clinical trial designs, while explicitly stating that applications should not propose clinical trials directly but focus on pre-trial research activities. The maximum funding available for each project is $100,000 over a two-year period, with applications due by October 17, 2024. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-160.html.
    Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity for Single-Site Investigator-Initiated Clinical Trials (R61/R33), aimed at supporting applications for clinical trials that test therapeutic, behavioral, or prevention strategies relevant to NHLBI's mission. This funding mechanism involves a bi-phasic award structure, with an initial R61 phase focused on protocol development followed by an R33 phase for trial execution, emphasizing comprehensive project management, subject recruitment, and community engagement. The initiative is particularly significant for advancing clinical research while promoting diversity among study participants and project teams. Interested applicants can find more details and submit proposals by September 12, 2025, and should direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.